# E-DA Hospital

Organization · id `cardio:org-e-da-hospital` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ROR record 00eh7f421](<https://ror.org/00eh7f421>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class other. Matched to ROR record 00eh7f421 by an exact name.

## The registry's words

- Sponsor name: E-DA Hospital
- Sponsor class: OTHER
- ROR name: E-Da Hospital

## Connected pages

- Sponsors: The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study) (`cardio:ct-nct01188824`)
- Sponsors: Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation (`cardio:ct-nct02666157`)
- Sponsors: The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation (`cardio:ct-nct04217135`)

## Provenance

Content hash: 0e45fe5eba4b85f4f07f6aa4d9696c00eecefb5c7058176e410ab6dd495ee925
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
